A Trim-RBD-GEM vaccine candidate protects mice from SARS-CoV-2

Virology. 2023 Aug:585:145-154. doi: 10.1016/j.virol.2023.06.005. Epub 2023 Jun 15.

Abstract

The SARS-CoV-2 pandemic has continued for about three years since emerging in late December 2019, resulting in millions of deaths. Therefore, there is an urgent need to develop a safe and effective vaccine to control SARS-CoV-2. In this study, we developed a bacterium-like particle vaccine that displays the SARS-CoV-2 receptor binding domain (RBD) (named Trim-RBD-GEM) using the GEM-PA system. We evaluated the immunogenicity and protective efficacy of the Trim-RBD-GEM vaccine with the oil-in-water adjuvant AddaVax in C57BL/6 N mice intramuscularly. We found that Trim-RBD-GEM&AddaVax induced high levels of humoral immunity in C57BL/6 N mice. Additionally, the lung virus loads in the immunized group were significantly decreased compared to the adjuvant control and mock groups. Therefore, this vaccine provides protection against lethal infection in a C57BL/6 N mouse model. Our Trim-RBD-GEM&AddaVax vaccine is potentially a promising, rapid, and safe subunit vaccine for preventing and controlling SARS-CoV-2.

Keywords: AddaVax adjuvant; Al(OH)(3) adjuvant; Bacterium-like particle; SARS-CoV-2 pandemic.

MeSH terms

  • Adjuvants, Immunologic
  • Animals
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19* / prevention & control
  • Mice
  • Mice, Inbred C57BL
  • SARS-CoV-2 / genetics
  • Spike Glycoprotein, Coronavirus
  • Vaccines*

Substances

  • Addavax
  • Vaccines
  • Adjuvants, Immunologic
  • Spike Glycoprotein, Coronavirus
  • Antibodies, Viral
  • Antibodies, Neutralizing
  • spike protein, SARS-CoV-2